Health Catalyst (NASDAQ:HCAT) Rating Increased to Buy at Zacks Investment Research
Health Catalyst (NASDAQ:HCAT – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday, Zacks.com reports. The firm presently has a $19.00 price target on the stock. Zacks Investment Research‘s price target points to a potential upside of 17.79% from the […]